護城河比較

Narrow, not wide, because the FY2026 10-K documents a strong installed base and a competitive position the company itself says is under erosion. On the asset side: revenue of $4.7 billion (29% growth in each of the last three fiscal years), 13,328 total customers up from 10,996, 790 of the Forbes Global 2000 contributing about 43% of revenue, 733 customers above $1 million in trailing-12-month product revenue up from 576, a 125% net revenue retention rate, and more than 1,050 issued U.S. patents. Against that, Item 1A states plainly that adopting open data formats like Apache Iceberg means 'there is less customer “lock in” when our products are used in external environments' and that 'our support of open data formats may also reduce switching costs between us and our competitors'; that AWS, Azure and GCP 'generally compete in all of our markets' while also supplying the infrastructure a 'substantial majority of our business is run on'; and that the company remains loss-making at $1.3 billion of net loss for the year.

來源：sec.gov

The FY2026 20-F rests on two entrenched positions: a commerce ecosystem the filing ties to 'the world's largest online retail market' with 'over 1.1 billion Internet users,' and a cloud business whose 'Cloud Intelligence Group's external revenue growth accelerated to 40% in the final quarter of fiscal 2026, with AI-related products accounting for 30% of this revenue.' Two durable franchises under one roof is a wide moat — bounded by China regulation and US ICTS cloud controls the same filing flags.

來源：sec.gov

Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K.

來源：sec.gov

The filing makes its own affirmative claim of network effects — 'Our business benefits from powerful network effects. ... The more customers adopt our platform, the more data can be exchanged with other Snowflake customers, partners, data providers, and data consumers' — but the load-bearing, quantified evidence in the document points to switching costs. The platform is sold as the way to 'consolidate data into a single source of truth,' and the disclosed economics of that consolidation are a 125% net revenue retention rate and 733 customers above $1 million in trailing product revenue. Item 1A confirms the mechanism by naming what is at risk: open formats produce 'less customer “lock in”' and 'may also reduce switching costs.' The filing frames lock-in, not network density, as the thing erosion would take away.

來源：sec.gov

The 20-F names 'the network effects of our ecosystems' among the factors its business depends on: Taobao and Tmall, Alipay, Amap and the rest compound as buyers, sellers and services reinforce each other across one integrated ecosystem.

來源：sec.gov

Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly.

來源：sec.gov

The 10-K contains no ranking, market-share figure, or claim of leadership, and it names no non-hyperscaler competitor by name. The band rests on disclosed scale — $4.7 billion of revenue, 13,328 customers, 9,060 employees across 36 countries — set against the filing's own statement that 'many of our competitors have substantially greater brand recognition, customer relationships, and financial, technical, and other resources than we do.' Co-leader among independent cloud data platforms; not a leader over AWS, Azure and GCP, which the filing says compete in all of its markets.

來源：sec.gov

The 20-F claims leadership in applied AI ('strengthened our leadership in applied AI') and roots the commerce business in the world's largest online retail market; Alibaba Cloud is the leading China hyperscaler pivoting to AI, per the segment discussion — a category leader in both its home markets.

來源：sec.gov

Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K.

來源：sec.gov

The consumption model plus 125% net revenue retention shows real expansion pricing, and the filing argues it competes on 'pricing transparency and optimized price-performance.' But Item 1A limits how far that goes: competition 'may negatively impact our ability to acquire new customers ... put downward pressure on our prices and gross margins'; the company 'may not be able to ... offer as many discounts or free services as our competitors'; results depend on 'changes in our pricing model, including in response to significant price discounts by our competitors' and on 'customer optimization efforts that result in reduced consumption.' On the cost side, 'our costs and gross margins are significantly influenced by the prices we are able to negotiate with these public cloud providers, which in certain cases are also our competitors.'

來源：sec.gov

Ecosystem lock-in and cloud scale support pricing, but the filing warns that if 'user activity and engagement in our ecosystem may decrease … our market share and profitability may be negatively affected,' and Chinese e-commerce/cloud competition is intense — real but capped pricing power.

來源：sec.gov

Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong.

來源：sec.gov

Sits at the enterprise data and governance layer of the AI stack, and the AI exposure is explicit rather than incidental: the filing brands the product the 'AI Data Cloud,' lists AI as a product category, and put Snowflake Intelligence, Cortex Agents and a Managed MCP Server into general availability during the fiscal year. It is a buyer of hyperscaler compute and of third-party frontier models — 'strategic partnerships with foundational model providers deliver state-of-the-art models natively within Snowflake Cortex AI,' with stated 'model neutrality' — and a supplier of governed enterprise data and GPU-backed managed compute to AI applications built on top.

Layer-8 hyperscaler + AI-application incumbent: Alibaba Cloud supplies AI compute and the Qwen models while the commerce ecosystem is a vast applied-AI distribution surface.

Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect.

• Analytics 前三 · 深 來源：sec.gov
• Data Engineering 挑戰者 · 中等 來源：sec.gov
• Snowflake Cortex AI 挑戰者 · 中等 來源：sec.gov
• Snowflake Marketplace and Data Collaboration 領先 · 深 來源：sec.gov
• Snowflake Postgres and Unistore 利基市場 · 低 來源：sec.gov
• Snowpark and Native Application Framework 利基市場 · 中等 來源：sec.gov

• Alibaba Cloud (Cloud Intelligence Group) 領先 · 深 來源：sec.gov
• Qwen large language models 領先 · 中等 來源：sec.gov
• Taobao and Tmall commerce ecosystem 領先 · 深 來源：sec.gov

• Mounjaro (tirzepatide) 前三 · 深 來源：sec.gov
• Verzenio (abemaciclib) 領先 · 中等 來源：living.tech
• Zepbound (tirzepatide) 領先 · 深 來源：sec.gov

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →

編輯先驗，未經回測。

檢視它究竟如何投票 →